CN102085396A - Medicine-carrying biodegradable vena cava filter and preparation method thereof - Google Patents
Medicine-carrying biodegradable vena cava filter and preparation method thereof Download PDFInfo
- Publication number
- CN102085396A CN102085396A CN2009101998300A CN200910199830A CN102085396A CN 102085396 A CN102085396 A CN 102085396A CN 2009101998300 A CN2009101998300 A CN 2009101998300A CN 200910199830 A CN200910199830 A CN 200910199830A CN 102085396 A CN102085396 A CN 102085396A
- Authority
- CN
- China
- Prior art keywords
- vena cava
- cava filter
- biodegradable
- filter
- methacrylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention belongs to the technical field of biological engineering and relates to a medicine-carrying biodegradable vena cava filter and a preparation method thereof. In the invention, methacrylic acid anhydride sebacic acid with bioactivity and di-(p-carboxyl phenoxyl) fat alkyl are used as polymerization raw materials, and nano polypeptide used as a reinforcing material is ultrasonically dispersed into polymerized monomers to obtain a columnar polymer material of certain degradation time through photocuring or thermocuring; and the columnar polymer material is etched into a vena cava filter with a barrel-shaped structure by a cutting machine, wherein low molecular heparin is used as an anticoagulant drug and a urokinase thrombolysis drug. By carrying the drugs, the vena cava filter not only can play a role of mechanically blocking thrombus, but also can be used as a drug releasing platform of anticoagulants and thrombolytics, can reduce the thrombophilia of the drugs, avoid postcava blockage caused by filter imbedding, effectively reduce the dosage of anticoagulation and thrombolytics drugs of the whole body and reduce the incidence of corresponding complications.
Description
Technical field
The invention belongs to technical field of bioengineering, be specifically related to biodegradable vena cava filter of a kind of medicine carrying and preparation method thereof.
Background technology
According to statistics, and pulmonary infarction (Pulmonary Embolism, sickness rate PE) is only second to coronary heart disease and hypertension in cardiovascular disease, and its mortality rate is only second to tumor and myocardial infarction.One group of autopsy data of China confirms that PE accounts for 11.0% of cardiovascular disease, and PE accounts for first of pulmonary vascular disease.Studies show that according to relevant vena cava filter can obviously reduce the incidence rate of recurrent PE.
Studies show that the Pulmonic embolus 75%～90% of thromboembolism derives from the thrombosis in deep veins of lower limb and the pelvic cavity venous plexus.In order to prevent or reduce the generation of pulmonary embolism, traditional surgical method often adopts the ligation postcava or weaves the filtration net with suture in postcava, in order to stop the intrasystem thrombosis of postcava.Clinical practice shows, the having a big risk of this type of operation, wound are heavy, and post-operative complication is many.In view of this, relevant technologies personnel imagine in the mode of percutaneous through the chamber, go into a filter that can stop thrombosis in that postcava is built-in.
Really can be used at first the Mobin-Uddin umbrella shape filter system that clinical filter is a reported first in 1967, form by umbrella shape filter, dispenser and year filter cone-shaped hood three parts.The beveled structure that is shaped as 6 stainless steel strips formation of filter, be covered with the silicone rubber membrane that flooded heparin on the stainless steel strip to reduce thrombosis, the aperture that 18 3mm diameters are arranged on the film passes through to keep blood flow, and 6 stainless steel strips terminal sharp-pointed can thrust the postcava wall with fixing filter; Dispenser wherein is the nylon conduit, and long 90cm, front end have the container that holds filter.Filter is inserted through the right internal jugular vein that cuts.Practice shows that postcava inaccessible ratio took place up to 60%～70% after complication rate height, the especially filter of use Mobin-Uddin put the people, was eliminated in recent years.
Kimray-Greenfield (KG) filter was in reported first in 1973, this KG is tapered, stretch out the shaped form stainless steel silk of 6 diameter 0.3mm, long 46mm from central collar, awl end maximum gauge 30rmn, initial also is to put the people through the jugular vein or the femoral vein that cut, improves later on and puts the people through the 24F catheter sheath.This KG has improved the postcava patency rate after filter is put the people greatly, but still has 15%～27% complication rate, and the catheter sheath diameter is big, and patient's wound is bigger, substituted by the GF of a new generation at present.
USP2009/0105747A1 discloses the vena cava filter that a kind of netted intravascular stent and beveled structure combine.Expansible intravascular stent provides fixing and supports the effect of umbrella shape filter, all is coated with the polymeric material with biocompatibility on surface wiry, improves the blood compatibility of assembling device.
Permanent wire chamber vein filter exists following insoluble problem: 1. the embolus capture ability is high more, and the incidence rate of postcava obturation at a specified future date is high more; 2. the thrombogenicity of metal filter itself; 3. permanent filter is as metallic foreign body home to return to problem in vivo etc.Still there is following dispute in the application of the provisional vena cava filter of metal: 1. how the thrombosis of being caught before the filter taking-up is handled; 2. behind the filter endothelialization (inserting), take out difficulty and increase above 12 days; 3. need second operation, increase patient's misery and medical expense.
Yet there are no the report of the relevant degradable vena cava filter of domestic and foreign literature.
Summary of the invention
The objective of the invention is provides biodegradable vena cava filter of a kind of medicine carrying and preparation method thereof in order to overcome the deficiencies in the prior art.
Particularly, the invention provides a kind of biodegradable polymer vena cava filter and preparation method thereof of medicine carrying.
Vena cava filter of the present invention strengthens nano material by polymer raw, and anticoagulant and thrombolytic drug are formed; Wherein, described polymer raw is selected from methacrylic acid anhydridization decanedioic acid and two (to the carboxyl phenoxy group) the fatty alkane of methacrylic acid anhydridization, the mass ratio of two (to the carboxyl phenoxy group) the fatty alkane of methacrylic acid anhydridization decanedioic acid and methacrylic acid anhydridization is 0-50: 50-100%, described enhancing nano material ultra-sonic dispersion is in photo-curing monomer, and nanoparticle reinforcing material addition is the 1-10% of polymerization single polymerization monomer quality; Described anticoagulant and thrombolytic drug are dispersed in the polymerization single polymerization monomer, and the medicine addition is the 1-5% of polymerization single polymerization monomer quality.
Vena cava filter of the present invention is barrel-shaped network structure, the one end opening, it is barrel-shaped that the other end is remained silent, drum head and bucket wall are etched into the scalable shape structure (as shown in Figure 1) that struts, vena cava filter of the present invention, the bucket wall can strut under external force, forms on the intravascular stent vasoactive wall of an expansion, have effect fixing and the support filter, drum head struts the back and has the effect of catching thrombosis as filter.
Than the wire chamber vein filter, the superiority of degradable polymer vena cava filter of the present invention is embodied in: (1) has excellent biological compatibility, particularly blood compatibility; (2) become nontoxic product and do not have immunogenicity by biodegradation; (3) provide temporary thrombosis to catch effect to narrow tube chamber, and do not have secular complication; (4) can be used as carrier and carry thrombolytic and anticoagulation medicine, obviously reduce complication, significantly improved the caval vein patency rate after filter is inserted.(5) the vivo degradation time is adjustable.
Vena cava filter of the present invention prepares by following method,
As polymer raw, will strengthen the nano material ultra-sonic dispersion with methacrylic acid anhydridization decanedioic acid and two (to the carboxyl phenoxy group) fatty alkane in photo-curing monomer, anticoagulant and thrombolytic drug will be dispersed in the polymerization single polymerization monomer by ultra-sonic dispersion; Add polymerization initiator then, pour in the glass mold, obtain the column polymeric material by photocuring or heat cure, cutting machine is etched into barrel-shaped cancellated vena cava filter with tubing.
Among the present invention, described nanoparticle reinforcing material is any of poly-peptide of nanometer or nanometer hydroxyapatite.Wherein the poly-peptide of nanometer is that (length of its kind and chain can be adjusted according to actual needs with poly-peptide.Wherein aminoacid can be selected L-aspartic acid, lysine, glutamic acid etc. for use) under weak solution state and uniform temperature, can self assembly in solvent form α-Luo Xuanjiegou with nanoscale, and very stable at normal temperatures.Width between the chain of this material is on the 0.5 Izod right side, and the width of the helical structure that self assembly forms also has only 10-20 dust (1 dust=0.1nm).Characteristics such as that hydroxyapatite has is nontoxic, nonirritant, good biological activity, excellent biological compatibility and bone conductibility, higher mechanical strength and chemical property are stable.But big because of the granule of hydroxyapatite and fragility, lack plasticity, vivo degradation slowly, biomechanical strength and resisting fatigue breakdown strength be lower, is difficult to be substituted fully, utilize by body, and its clinical practice is restricted.
Nanometer hydroxyapatite of the present invention is for obtaining the commercial product of industrialized production and application.Hydroxyapatite in the skeleton mainly is a nanoscale whiskers body structure, and nano level hydroxyapatite is more similar to people's in-vivo tissue composition, has better biology performance.
Among the present invention, described polymerization initiator comprises two classes: light trigger and thermal initiator.Light trigger comprises ultraviolet initiator: 2, and 2-dimethoxy-2-phenyl 1-Phenylethanone. (DMPA) and visible light initiator: camphorquinone/triethanolamine system (CQ/TEA), the light trigger addition is the 0.1-1% of polymerization single polymerization monomer quality.The used uviol lamp wavelength of ultraviolet initiator initiated polymerization is 365nm.Thermal initiator adopts common azo compound and peroxide, adopts benzoyl peroxide as thermal initiator among the present invention, and consumption is the 1-3% of polymerization single polymerization monomer amount.
Among the present invention, the medicine of vena cava filter institute load is anticoagulation medicine and a thrombolytic drug commonly used clinically.Wherein, the preferred Low molecular heparin of described anticoagulant, the preferred urokinase of thrombolytic drug.
Among the present invention, the method for described cutting columnar material is according to setting pattern columnar material to be etched into distensible network structure by laser cutting machine.
Vena cava filter adopts in the present invention is poly-anhydride material (the L anger of Massachusetts Institute Technology equal find the beginning of the eighties the novel synthesising biological degradable high polymer material of a class), and it has excellent biological compatibility, surface erosion degradability, degradation speed is adjustable and excellent properties such as workability.Among the present invention, the preparation of two (to the carboxyl phenoxy group) hexanes (MCPH) of used polymerization single polymerization monomer methacrylic acid anhydridization decanedioic acid (MSA) and methacrylic acid anhydridization all has description on pertinent literature, and concrete preparation process is as follows respectively:
Take by weighing decanedioic acid 0.1mol (20.2g) in the single port flask, add 0.25mol (40ml) methacrylic anhydride (MA), flask is placed oil bath, put into the tetrafluoro stirrer and start electromagnetic agitation, control reaction temperature is at 80 ℃.React about about 1 hour SA complete reaction and become clear liquid.Continue reaction 0.5 hour, obtain achromaticity and clarification liquid.With boiling range is 90-120 ℃ petroleum ether extraction product three times, takes off a layer colourless transparent liquid, and residual petroleum ether and methacrylic anhydride, methacrylic anhydride are removed in distilling under reduced pressure under 80 ℃ of conditions.The heavy-gravity liquid of gained water white transparency is product MSA.
Take by weighing 1 after making with extra care, two (to the carboxyl phenoxy group) the hexane 35.8g (0.1mol) of 6-place round-bottomed flask, add the methacrylic anhydride of (0.25mol), electromagnetic agitation, and oil bath is heated to 140 ℃.Product becomes light yellow transparent liquid when reacting about 4 hours, treats to be transformed into fully and continues reaction 1 hour behind the liquid again, stops heating.Remove oil bath and make product be cooled to room temperature, obtain transparent faint yellow liquid.With boiling range is 90-120 ℃ of petroleum ether extraction three times, and products therefrom filters with sand core funnel.Resulting liquid is carried out distilling under reduced pressure under 100 ℃, remove residual petroleum ether, methacrylic acid and unreacted completely methacrylic acid join, the last transparent clarifying weak yellow liquid of gained is MCPH, sealing is preserved at low temperatures.
The present invention adopts has good mechanical strength and bioactive poly-anhydride as filter material, and it has the degradation characteristic of surface erosion, degraded that can be stable and have linear release kinetic curve.The nanoparticle that adopts biologically active further improves the mechanical property and the biocompatibility of material as reinforcing material.
Description of drawings
Fig. 1 is the barrel-shaped netted scalable shape structural representation that struts of vena cava filter of the present invention.
The specific embodiment
Provided more detailed description of the present invention with embodiment below, helped to understand the present invention.Yet, this should be interpreted as limitation of the scope of the invention.
Embodiment 1 preparation methacrylic acid anhydridization decanedioic acid (MSA)
Take by weighing decanedioic acid 0.1mol (20.2g) in the single port flask, add 0.25mol (40ml) methacrylic anhydride (MA), flask is placed oil bath, put into the tetrafluoro stirrer and start electromagnetic agitation, control reaction temperature is at 80 ℃.React about about 1 hour SA complete reaction and become clear liquid.Continue reaction 0.5 hour, obtain achromaticity and clarification liquid.With boiling range is 90-120 ℃ petroleum ether extraction product three times, takes off a layer colourless transparent liquid, and residual petroleum ether and methacrylic anhydride, methacrylic anhydride are removed in distilling under reduced pressure under 80 ℃ of conditions.The heavy-gravity liquid of gained water white transparency is product MSA.
Embodiment 2 preparation methacrylic acid anhydridizations 1, two (to the carboxyl phenoxy group) hexanes (MCPH) of 6-
27.6g (0.2mol) P-hydroxybenzoic acid, 16g (0.4mol) sodium hydroxide are dissolved in 300ml water, place the 500ml three-neck flask, stir and dropwise add 24.6g (0.Im ol) dibromo-hexane (1hr adds) reflux simultaneously down, behind the 5hr, add 4g (0.1mol) sodium hydrate solid, continue to reflux 2 hours.Stop heating, with the reactant standing over night.Sucking filtration, precipitation is used the 40ml methanol wash, is dissolved in immediately in the 100ml water.This solution is heated to 60-70 ℃, with the 6mol/L sulfuric acid acidation till no longer produce white precipitate.Sucking filtration is deposited in 40 ℃ of vacuum dryings while hot, gets white powder 22.3g (51%).IR (YBr) v (cm '): 3300 (wide, K AP-OH), 1675 (shuttle acid C=0), 1604,1513 (phenyl ring C=C), 1255,1169 (aryl oxide C-0).
The CPH solid 35.8g (0.1mol) that takes by weighing after making with extra care places round-bottomed flask, adds the methacrylic anhydride of (0.25mol), electromagnetic agitation, and oil bath is heated to 140 ℃.Product becomes light yellow transparent liquid when reacting about 4 hours, treats to be transformed into fully and continues reaction 1 hour behind the liquid again, stops heating.Remove oil bath and make product be cooled to room temperature, obtain transparent faint yellow liquid.With boiling range is 90^-120 ℃ of petroleum ether extraction three times, and products therefrom filters with sand core funnel.Resulting liquid is carried out distilling under reduced pressure under 100 ℃, remove residual petroleum ether, methacrylic acid and unreacted completely methacrylic acid join, the last transparent clarifying weak yellow liquid of gained is MCPH.Sealing is preserved at low temperatures.
Embodiment 3
Take by weighing two (to the carboxyl phenoxy group) hexane (MCPH) 5g of methacrylic acid anhydridization decanedioic acid (MSA) 5g and methacrylic acid anhydridization, put into beaker, add Low molecular heparin 0.25g, urokinase 0.25g, add poly-peptide particle 0.1g then, light trigger 2,2-dimethoxy-2-phenyl 1-Phenylethanone. (DMPA) 0.1g, electromagnetic agitation 30min, ultrasonic 30min, pour in the glass mold, at wavelength is 365nm, and the uviol lamp of power 500W is irradiation 5min down, obtains the columnar material of different-diameter, can cut into different length as required; PROSTENT 1 laser cutting machine is pressed AlphaCAM (LICOM) graphic design software design configuration, and computer control is etched into the network structure form with tubing down; In PBS solution (phosphate buffer solution), measuring its degradation time is 50 days.
Embodiment 4
Take by weighing two (to the carboxyl phenoxy group) hexane (MCPH) 5g of methacrylic acid anhydridization decanedioic acid (MSA) 5g and methacrylic acid anhydridization, put into beaker, add Low molecular heparin 0.05g, urokinase 0.05g, add hydroxyapatite nano particle 1.0g then, benzoyl peroxide 0.3g, electromagnetic agitation 30min, ultrasonic 30min, pour in the cylindrical mold, solidify 2h respectively, to the columnar material of different-diameter at 70 ℃ and 80 ℃, can cut into different length as required; The PROSTENT1 laser cutting machine is pressed AlphaCAM (LICOM) graphic design software design configuration, and computer control is etched into the network structure form with tubing down; In PBS solution (phosphate buffer solution), measuring its degradation time is 35 days.
Embodiment 5
Take by weighing methacrylic acid anhydridization decanedioic acid (MSA) 10g, put into beaker, add donor Low molecular heparin 0.2g, urokinase 0.05g adds hydroxyapatite nano material 1.0g, light trigger DMPA 0.1g, electromagnetic agitation 30min, ultrasonic 30min pours in the glass mold, is 365nm at wavelength, the uviol lamp of power 500W is irradiation 5min down, obtain columnar material, can cut into different length as required; PROSTENT 1 laser cutting machine is pressed Alpha CAM (LICOM) graphic design software design configuration, and computer control is etched into ripple type network structure form with tubing down; In PBS solution, measuring its degradation time is 3 days.
Embodiment 6
Take by weighing (MCPH) 10g of two (to the carboxyl phenoxy group) hexanes of methacrylic acid anhydridization, put into beaker, add the low sub-heparin 0.05g of donor, urokinase 0.20g, nano hydroxyl phosphorite crystal 0.5g, thermal initiator benzoyl peroxide 0.1g, electromagnetic agitation 30min, ultrasonic 30min pours in the glass mold, is 365nm at wavelength, the uviol lamp of power 500W is irradiation 5min down, obtain the tubular material of different-diameter, can cut into different length as required; PROSTENT 1 laser cutting machine is pressed Alpha CAM (LICOM) graphic design software design configuration, and computer control is etched into honeycomb type network structure form with tubing down; In PBS solution, measuring its degradation time is 280 days.
Claims (10)
1. the biodegradable vena cava filter of medicine carrying is characterized in that, by polymer raw, strengthens nano material, and anticoagulant and thrombolytic drug are formed; Wherein, described polymer raw is selected from methacrylic acid anhydridization decanedioic acid and two (to the carboxyl phenoxy group) the fatty alkane of methacrylic acid anhydridization, described enhancing nano material ultra-sonic dispersion is in photo-curing monomer, and described anticoagulant and thrombolytic drug are dispersed in the polymerization single polymerization monomer.
2. by the biodegradable vena cava filter of the described medicine carrying of claim 1, it is characterized in that the mass ratio of two (to the carboxyl phenoxy group) the fatty alkane of described methacrylic acid anhydridization decanedioic acid and methacrylic acid anhydridization is 0-50: 50-100%.
3. by the biodegradable vena cava filter of the described medicine carrying of claim 1, it is characterized in that described nanoparticle reinforcing material is selected from any of poly-peptide of nanometer or nanometer hydroxyapatite.
4. by the biodegradable vena cava filter of the described medicine carrying of claim 1, it is characterized in that described nanoparticle reinforcing material addition is the 1-10% of polymerization single polymerization monomer quality.
5. by the biodegradable vena cava filter of the described medicine carrying of claim 1, it is characterized in that described anticoagulant and thrombolytic drug addition are the 1-5% of polymerization single polymerization monomer quality.
6. method for preparing the biodegradable vena cava filter of the described medicine carrying of claim 1 is characterized in that by following step:
As polymer raw, will strengthen the nano material ultra-sonic dispersion with methacrylic acid anhydridization decanedioic acid and two (to the carboxyl phenoxy group) fatty alkane in photo-curing monomer, anticoagulant and thrombolytic drug will be dispersed in the polymerization single polymerization monomer by ultra-sonic dispersion; Add polymerization initiator then, pour in the glass mold, obtain the column polymeric material by photocuring or heat cure, cutting machine is etched into barrel-shaped cancellated vena cava filter with tubing.
7. by the method for claim 6, it is characterized in that described polymerization initiator is selected from light trigger or thermal initiator.
8. by the method for claim 7, it is characterized in that described light trigger is 2,2-dimethoxy-2-phenyl 1-Phenylethanone., described thermal initiator is a benzoyl peroxide.
9. by the method for claim 6, it is characterized in that described barrel-shaped cancellated vena cava filter is an end opening, it is barrel-shaped that the other end is remained silent, and drum head and bucket wall are etched into the scalable shape structure that struts.
10. by the biodegradable vena cava filter of the described medicine carrying of claim 1, it is characterized in that described anticoagulant is a Low molecular heparin, described thrombolytic drug is a urokinase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101998300A CN102085396A (en) | 2009-12-02 | 2009-12-02 | Medicine-carrying biodegradable vena cava filter and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101998300A CN102085396A (en) | 2009-12-02 | 2009-12-02 | Medicine-carrying biodegradable vena cava filter and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102085396A true CN102085396A (en) | 2011-06-08 |
Family
ID=44097555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101998300A Pending CN102085396A (en) | 2009-12-02 | 2009-12-02 | Medicine-carrying biodegradable vena cava filter and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102085396A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107303209A (en) * | 2016-04-17 | 2017-10-31 | 郭红 | With the tubular intravascular stent that can be bent from circumference to slot |
| CN109963527A (en) * | 2016-12-16 | 2019-07-02 | 北京阿迈特医疗器械有限公司 | Biodegradable thrombus filter and preparation method thereof, purposes and conveying device |
-
2009
- 2009-12-02 CN CN2009101998300A patent/CN102085396A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107303209A (en) * | 2016-04-17 | 2017-10-31 | 郭红 | With the tubular intravascular stent that can be bent from circumference to slot |
| CN107303209B (en) * | 2016-04-17 | 2019-05-24 | 郭红 | With circumference to slot can be with curved tubular intravascular stent |
| CN109963527A (en) * | 2016-12-16 | 2019-07-02 | 北京阿迈特医疗器械有限公司 | Biodegradable thrombus filter and preparation method thereof, purposes and conveying device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106955140B (en) | Thrombus taking support and thrombus taking device | |
| CN103142335B (en) | A kind of thermoplastic degradable fiber woven stent and preparation method thereof | |
| CN100409818C (en) | Reusable temporary thrombus filter | |
| RU2010135977A (en) | METHODS AND DEVICE FOR RECOVERY FLOW | |
| CN204909721U (en) | Filter | |
| US10092663B2 (en) | Polymers | |
| JP5612279B2 (en) | Non-human animal model of myocardial infarction and production method thereof | |
| CN107889455A (en) | Biocompatibility biomedicine locking device | |
| AU2014278745B2 (en) | Polymer compositions with enhanced radiopacity | |
| CN203885554U (en) | Spring ring | |
| CN102085396A (en) | Medicine-carrying biodegradable vena cava filter and preparation method thereof | |
| CN101491465A (en) | Blood vessel filter | |
| CN205433997U (en) | Die cavity vein filter of can changeing | |
| CN102755668A (en) | Medical plastic bone cement | |
| CN104927777A (en) | Preparation method and application of phase change energy storage microcapsules | |
| CN107174373B (en) | Filter unit | |
| CN200991273Y (en) | Stepladder-shape spring ring for embolism aneurysm | |
| CN110420175A (en) | A kind of injection-type amino acid derivativges small molecule gel rubber material and its application | |
| CN208741066U (en) | A kind of thrombus takes bolt device | |
| CN105877794B (en) | A kind of ventricle capacity-reduction device | |
| CN205322407U (en) | Degradable heart left auricle of heart plugging device can develop | |
| CN209630389U (en) | A kind of embolization catheter | |
| CN204169954U (en) | A kind of degradable human body alimentary canal support that effectively can prevent displacement, reduce hypertrophy | |
| WO2004069294A1 (en) | Injectable gel-forming compositions based on cross-linked and non-cross-linked polymers and the use thereof | |
| CN101357244B (en) | Preparation method of nano particle reinforced light-solidifying poly-anhydride drug-loading polymer rack |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110608 |